Navigation Links
Perrigo Announces FDA Final Approval for Desloratadine
Date:12/27/2011

ALLEGAN, Mich., Dec. 27, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for Desloratadine tablets (5 mg).  Perrigo had been sued for patent infringement based upon its filing of an ANDA containing a Paragraph IV certification and settled the case in 2008. Under the terms of the settlement, Perrigo can commercially launch its generic Desloratadine product on July 1, 2012, or earlier in certain circumstances. The new product launch may be a prescription or over-the-counter (OTC) product depending on its status at the time of launch. 

This product is an AB-rating as equivalent to Schering-Plough's Clarinex® tablets (5 mg) indicated for the treatment of seasonal allergic rhinitis and perennial allergic rhinitis. Sales for the brand were approximately $185 million, according to Wolters Kluwer data.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This is another example of Perrigo's continued commitment to bring new products to the market. Perrigo continues to be focused on our mission of making quality healthcare more affordable for consumers."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section
'/>"/>

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. Perrigo Company Announces Dividend Increase
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
9. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Perrigo Company To Present at the Sidoti Emerging Growth Conference
11. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... July 6, 2015 E-QURE Corp (OTCQB: EQUR), ... live at VirtualInvestorConferences.com on July 9, 2015. ... http://tinyurl.com/e-qure-presentation This will be a ... ask the company questions in real-time - both in ... trade booth." If attendees are not able to join ...
(Date:7/6/2015)... -- Celtaxsys, Inc., a clinical stage pharmaceutical development company ... orphan inflammatory disease indications, announced today that it has ... (FDA) to begin a Phase 2 clinical trial of ... patients in the US. The regulatory submissions to the ... be filed soon after. This groundbreaking clinical study, testing ...
(Date:7/6/2015)... , July 6, 2015  OncoSec Medical Inc. ... intratumoral cancer immunotherapies, today announced the appointment of ... of Vice President of Market Development, effective July 6, ... for evaluating, designing, and executing on the company,s market ... "I,m very excited to welcome Joann to the ...
Breaking Medicine Technology:E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3
(Date:7/7/2015)... ... 07, 2015 , ... CSG Government Solutions, a ... the Department of Vermont Health Access to provide Quality Assurance (QA) and Independent ... Integrated Contact Center System project. , Vermont is implementing a strategic approach to ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Respected southern ... awards in 2015, marking him as an attorney who has sharp legal skills ... both a Client Distinction Award for 2015 from Martindale-Hubbell and a Top 10 Award ...
(Date:7/6/2015)... Angeles, CA (PRWEB) , ... July 06, 2015 , ... On June 22, 2015, Fox News in a report titled ... by the time they turn age 35 a quarter of all women in the U.S. will ... hair loss is stigmatized and rarely discussed. One woman, a former beauty queen, who ...
(Date:7/6/2015)... ... ... The Asian-Pacific market for rheumatoid arthritis therapeutics reached a value of more than ... over 3.2 percent in the years to come to hit the USD 6.9 billion ... anticipated launch of a number of promising pipeline candidates and an increase in the ...
(Date:7/6/2015)... Chester, NJ (PRWEB) , ... July 06, 2015 ... ... CancerHopeNetwork.org. The redesigned site allows newly-diagnosed cancer patients, caregivers and medical professionals to ... who has survived the same cancer. , “Receiving a cancer diagnosis is often ...
Breaking Medicine News(10 mins):Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 2Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 3Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2
... UC Davis professor Adela de la Torre, a national ... five-year, $4.8 million,federal grant to discover the best ways ... The study, called "Ninos Sanos, Familia Sana" (Healthy Children,Healthy ... of,Firebaugh and San Joaquin. "More than four in ...
... The experimental agent selumetinib has shown promising results ... multi-institutional clinical trial led by cancer researchers at The ... (ARRY-142886), blocks a protein called MEK, which cancer cells ... malignancy of cells lining the bile ducts and gall ...
... HealthDay Reporter , MONDAY, April 25 (HealthDay News) -- ... along with the bullies themselves -- made more frequent visits ... and injuries than their other classmates, according to new research ... be getting frequent stomachaches from being picked on," said Eric ...
... Reporter , MONDAY, April 25 (HealthDay News) -- A new study ... -- in areas such as job success, education and any brushes ... motivated you are when you take the test. In other ... life, "but it might not predict it for the reason you ...
... G. James Cancer Hospital and Richard J. Solove Research ... convening a high-level group of stakeholders to discuss ... drugs for the treatment of cancer. ... (FDA) released a Guidance Document addressing the protocol researchers ...
... MONDAY, April 25 (HealthDay News) -- New research suggests that ... regulating a brain wave known as the alpha rhythm, which ... small study, researchers found that those participants using meditation were ... told where to direct their attention -- after they finished ...
Cached Medicine News:Health News:$4.8 million study will fight child obesity in California 2Health News:$4.8 million study will fight child obesity in California 3Health News:$4.8 million study will fight child obesity in California 4Health News:Targeted agent selumetinib shows promise in biliary cancer 2Health News:Bullied Kids Showing Up in School Nurses' Offices 2Health News:Bullied Kids Showing Up in School Nurses' Offices 3Health News:Do IQ Tests Measure More Than Intelligence? 2Health News:Public session of the Cancer Drug Development Roundtable at Ohio State 2Health News:Meditation May Help Brain Block Out Distractions 2
... Portable Slit-Lamp. Rechargeable, cordless ... for any purpose , Easy selection ... blue filter , Extra-bright halogen lamp ... main and extra ,power pack , ...
The PillCam™ ESO video capsule is specifically designed to view the inner lining of the Esophagus. The capsule is equipped with miniature cameras on both ends and is about the size of a multi-v...
World's first commercially available vacuum assisted biopsy device for MRI....
... Now you can perform stereotactic, ultrasound ... the convenience of your office. Use the ... safer, easier and more clinically advanced method ... its best for the women who trust ...
Medicine Products: